CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction
Cardiovascular disorders, especially acute coronary syndromes, are among the leading causes of mortality worldwide, and advanced glycation end products (AGEs) are associated with cardiovascular disease and serve as biomarkers for diagnosis and prediction. In this study, we investigated the utility o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/3/434 |
| _version_ | 1827697937501650944 |
|---|---|
| author | Govigerel Bayarsaikhan Delger Bayarsaikhan Pyung Chun Oh Woong Chol Kang Bonghee Lee |
| author_facet | Govigerel Bayarsaikhan Delger Bayarsaikhan Pyung Chun Oh Woong Chol Kang Bonghee Lee |
| author_sort | Govigerel Bayarsaikhan |
| collection | DOAJ |
| description | Cardiovascular disorders, especially acute coronary syndromes, are among the leading causes of mortality worldwide, and advanced glycation end products (AGEs) are associated with cardiovascular disease and serve as biomarkers for diagnosis and prediction. In this study, we investigated the utility of AGEs as prognostic biomarkers for acute myocardial infarction (AMI). We measured AGEs in serum samples of AMI patients (<i>N</i> = 27) using the cupric ion reducing antioxidant capacity (CUPRAC) method on days 0, 2, 14, 30, and 90 after AMI, and the correlation of serum AGE concentration and post-AMI duration was determined using Spearman’s correlation analysis. Compared to total serum protein, the level of CUPRAC reactive AGEs was increased from 0.9 to 2.1 times between 0–90 days after AMI incident. Furthermore, the glycation pattern and Spearman’s correlation analysis revealed four dominant patterns of AGE concentration changes in AMI patients: stable AGE levels (straight line with no peak), continuous increase, single peak pattern, and multimodal pattern (two or more peaks). In conclusion, CUPRAC-reactive AGEs can be developed as a potential prognostic biomarker for AMI through long-term clinical studies. |
| first_indexed | 2024-03-10T13:19:41Z |
| format | Article |
| id | doaj.art-cb88ada0e5d4458da893fe8281f282ad |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T13:19:41Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-cb88ada0e5d4458da893fe8281f282ad2023-11-21T10:08:24ZengMDPI AGAntioxidants2076-39212021-03-0110343410.3390/antiox10030434CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial InfarctionGovigerel Bayarsaikhan0Delger Bayarsaikhan1Pyung Chun Oh2Woong Chol Kang3Bonghee Lee4Center for Genomics and Proteomics, Lee Gil Ya Cancer and Diabetes Institute, School of Medicine, Gachon University, Incheon City 406-840, KoreaCenter for Genomics and Proteomics, Lee Gil Ya Cancer and Diabetes Institute, School of Medicine, Gachon University, Incheon City 406-840, KoreaGil Medical Center, Department of Cardiology, Gachon University of Medicine and Science, Incheon City 405-760, KoreaGil Medical Center, Department of Cardiology, Gachon University of Medicine and Science, Incheon City 405-760, KoreaCenter for Genomics and Proteomics, Lee Gil Ya Cancer and Diabetes Institute, School of Medicine, Gachon University, Incheon City 406-840, KoreaCardiovascular disorders, especially acute coronary syndromes, are among the leading causes of mortality worldwide, and advanced glycation end products (AGEs) are associated with cardiovascular disease and serve as biomarkers for diagnosis and prediction. In this study, we investigated the utility of AGEs as prognostic biomarkers for acute myocardial infarction (AMI). We measured AGEs in serum samples of AMI patients (<i>N</i> = 27) using the cupric ion reducing antioxidant capacity (CUPRAC) method on days 0, 2, 14, 30, and 90 after AMI, and the correlation of serum AGE concentration and post-AMI duration was determined using Spearman’s correlation analysis. Compared to total serum protein, the level of CUPRAC reactive AGEs was increased from 0.9 to 2.1 times between 0–90 days after AMI incident. Furthermore, the glycation pattern and Spearman’s correlation analysis revealed four dominant patterns of AGE concentration changes in AMI patients: stable AGE levels (straight line with no peak), continuous increase, single peak pattern, and multimodal pattern (two or more peaks). In conclusion, CUPRAC-reactive AGEs can be developed as a potential prognostic biomarker for AMI through long-term clinical studies.https://www.mdpi.com/2076-3921/10/3/434albuminglycationCUPRAChuman serumAMI |
| spellingShingle | Govigerel Bayarsaikhan Delger Bayarsaikhan Pyung Chun Oh Woong Chol Kang Bonghee Lee CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction Antioxidants albumin glycation CUPRAC human serum AMI |
| title | CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction |
| title_full | CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction |
| title_fullStr | CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction |
| title_full_unstemmed | CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction |
| title_short | CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction |
| title_sort | cuprac reactive advanced glycation end products as prognostic markers of human acute myocardial infarction |
| topic | albumin glycation CUPRAC human serum AMI |
| url | https://www.mdpi.com/2076-3921/10/3/434 |
| work_keys_str_mv | AT govigerelbayarsaikhan cupracreactiveadvancedglycationendproductsasprognosticmarkersofhumanacutemyocardialinfarction AT delgerbayarsaikhan cupracreactiveadvancedglycationendproductsasprognosticmarkersofhumanacutemyocardialinfarction AT pyungchunoh cupracreactiveadvancedglycationendproductsasprognosticmarkersofhumanacutemyocardialinfarction AT woongcholkang cupracreactiveadvancedglycationendproductsasprognosticmarkersofhumanacutemyocardialinfarction AT bongheelee cupracreactiveadvancedglycationendproductsasprognosticmarkersofhumanacutemyocardialinfarction |